We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

270 hedge funds and large institutions have $2.38B invested in Myriad Genetics in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 109 increasing their positions, 90 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 90

1% more funds holding

Funds holding: 267 → 270 (+3)

6% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 48

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less capital invested

Capital invested by funds: $2.62B → $2.38B (-$245M)

74% less call options, than puts

Call options by funds: $43.4M | Put options by funds: $168M

Holders
270
Holders Change
+3
Holders Change %
+1.12%
% of All Funds
7.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
51
Increased
109
Reduced
90
Closed
48
Calls
$43.4M
Puts
$168M
Net Calls
-$125M
Net Calls Change
-$87.4M

Top Buyers

1
LCG
Luxor Capital Group
New York
+$73.2M
2
FTCM
Fir Tree Capital Management
New York
+$55.6M
3
Capital Research Global Investors
Capital Research Global Investors
California
+$47.8M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$38.8M
5
SCM
Snow Capital Management
Pennsylvania
+$38.6M

Top Sellers

1
MNA
Manning & Napier Advisors
New York
-$173M
2
Renaissance Technologies
Renaissance Technologies
New York
-$54.9M
3
SFM
Systematic Financial Management
New Jersey
-$54.5M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$26.2M
5
Goldman Sachs
Goldman Sachs
New York
-$26.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$20M +$5.23M +206,616 +28%
AQR Capital Management
27
AQR Capital Management
Connecticut
$19.1M +$15.9M +627,967 +223%
CM
28
CS McKee
Pennsylvania
$18.2M -$714K -28,240 -3%
DGI
29
Disciplined Growth Investors
Minnesota
$17.4M +$839K +33,157 +4%
UOC
30
UBS O'Connor
Illinois
$16.8M -$7.31M -289,206 -27%
SCM
31
Scopia Capital Management
New York
$16M +$19.3M +762,400 New
SGAM
32
Smith Group Asset Management
Texas
$15.9M – – –
KG
33
Killen Group
Pennsylvania
$15.7M +$19M +750,090 New
Morgan Stanley
34
Morgan Stanley
New York
$15.5M +$5M +197,729 +37%
American Century Companies
35
American Century Companies
Missouri
$15.4M +$7.37M +291,294 +66%
UBS AM
36
UBS AM
Illinois
$15M +$1.62M +64,166 +10%
BTW
37
Boston Trust Walden
Massachusetts
$14.7M -$14.7M -579,986 -45%
KIM
38
Kestrel Investment Management
California
$14.7M -$3.92M -154,925 -18%
Goldman Sachs
39
Goldman Sachs
New York
$14M -$26.1M -1,032,704 -61%
Deutsche Bank
40
Deutsche Bank
Germany
$14M -$12.7M -501,837 -43%
HA
41
Heartland Advisors
Wisconsin
$13.8M +$11.5M +456,000 +228%
Norges Bank
42
Norges Bank
Norway
$13.7M +$1.51M +59,549 +10%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$13.7M +$7.9M +312,448 +124%
HM
44
HealthCor Management
New York
$13.6M +$16.4M +650,000 New
AL
45
AJO LP
Pennsylvania
$13.6M +$6.51M +257,300 +66%
OAM
46
Oxford Asset Management
United Kingdom
$13.2M +$9.93M +392,517 +167%
FQ
47
First Quadrant
California
$12.9M +$8.42M +332,800 +119%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$12M +$3.7M +146,413 +34%
PP
49
Prudential plc
United Kingdom
$11.9M – – –
FCM
50
Frontier Capital Management
Massachusetts
$11.3M -$174K -6,890 -1%
1
2
3 4 5

MYGN Hedge Fund Activity: Q4 2013 in Review

270 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2013, worth a combined $2.38B — down 9.4% from $2.62B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new MYGN positions and 48 closed out — a net gain of 3 holders — while 109 added to existing stakes and 90 trimmed.

The largest buyer was Luxor Capital Group, adding an estimated $73.2M. The largest seller was Manning & Napier Advisors, exiting entirely with an estimated $173M sold.

  • 270 institutional investors held Myriad Genetics (MYGN) as of Q4 2013, up from 267 in Q3 2013.
  • Funds reported $2.38B of Myriad Genetics stock for Q4 2013, down 9.4% quarter-over-quarter.
  • 51 funds opened new Myriad Genetics positions in Q4 2013 and 48 closed out, a net change of +3 holders.
  • The largest Myriad Genetics buyer in Q4 2013 was Luxor Capital Group, an estimated $73.2M added.
  • The largest Myriad Genetics seller in Q4 2013 was Manning & Napier Advisors, an estimated $173M sold.

Based on aggregated 13F filings for Q4 2013.